CATUG Biotechnology

About CATUG Biotechnology

CATUG Biotechnology, established in 2021, operates as a specialized Contract Research, Development, and Manufacturing Organization (CRDMO) with a strategic focus on nucleic acid-based therapeutics. The company provides comprehensive, end-to-end services for the gene and cell therapy (GCT) and nucleic acid drug sectors, with a particular emphasis on mRNA vaccines and therapeutics. The business model is centered on providing one-stop CDMO services that span the entire product lifecycle, from initial research and development through to clinical application and commercial manufacturing. This positions the company as a strategic partner for pharmaceutical and biotech clients, which have included prominent names like Moderna, Pfizer, and Regeneron.

Co-founded by Dr. Lin Jin, who serves as the company's President and CTO, CATUG leverages deep expertise in the field. The company's service offerings are built upon four core technology platforms: plasmid DNA, mRNA, lipid nanoparticle (LNP) delivery systems, and analytical quality control (QC). This integrated structure allows CATUG to offer customized solutions, including large-scale GMP plasmid manufacturing, flexible mRNA in vitro transcription (IVT), innovative LNP encapsulation, and sterile fill-finish services with an annual capacity of 10 million vials. For its clients, this translates to an accelerated path from development to patient access, ensuring quality and regulatory compliance. The company has developed over 80 platform methods for the release, stability testing, and characterization of DNA, RNA, and nanoparticle formulations.

Since its inception, CATUG has demonstrated rapid growth and strategic expansion. After its founding in Suzhou, China, the company established a presence in Cambridge, Massachusetts, and in 2024, moved its global headquarters to Basel, Switzerland, placing it in a key European biotech hub to enhance partnerships and market proximity. This move was supported by a partnership with the Swiss Innovation Park (SIP) at the Novartis Campus. The company's progress is backed by significant venture capital, having raised $14 million in an early-stage VC round in June 2024. Its investor base includes firms such as Efung Capital, China InnoVision Capital, and Northern Light Venture Capital. CATUG has also formed strategic partnerships, such as a joint lab with Crystal Bio to advance nucleic acid analytical services in North America, and collaborations with CellOrigin Biotech and 3D Medicines Inc. to develop CAR-based immunotherapies.